Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average) (2023 - 2025)
Historic Shares Outstanding (Weighted Average) for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $168.8 million.
- Compass Therapeutics' Shares Outstanding (Weighted Average) rose 2267.44% to $168.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.8 million, marking a year-over-year increase of 2267.44%. This contributed to the annual value of $137.4 million for FY2024, which is 815.34% up from last year.
- Compass Therapeutics' Shares Outstanding (Weighted Average) amounted to $168.8 million in Q3 2025, which was up 2267.44% from $138.3 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Shares Outstanding (Weighted Average) registered a high of $168.8 million during Q3 2025, and its lowest value of $126.4 million during Q1 2023.
- For the 3-year period, Compass Therapeutics' Shares Outstanding (Weighted Average) averaged around $136.6 million, with its median value being $137.4 million (2024).
- Within the past 5 years, the most significant YoY rise in Compass Therapeutics' Shares Outstanding (Weighted Average) was 2267.44% (2025), while the steepest drop was 50.37% (2025).
- Quarter analysis of 3 years shows Compass Therapeutics' Shares Outstanding (Weighted Average) stood at $127.0 million in 2023, then grew by 8.15% to $137.4 million in 2024, then rose by 22.87% to $168.8 million in 2025.
- Its Shares Outstanding (Weighted Average) was $168.8 million in Q3 2025, compared to $138.3 million in Q2 2025 and $138.2 million in Q1 2025.